• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Therapeutic Areas
  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

App Note: Human renal proximal tubule-on-a-chip for nephrotoxicity and drug interaction studies


Robust validated proximal tubule-on-a-chip

Drug-induced organ toxicity accounts for 30% of all drugs that fail prior to reaching the market. Within this, nephrotoxicity accounts for 2% of failures in the preclinical stages and 19% of all failures in Phase III. There is a significant translational gap between the preclinical models of nephrotoxicity and their predictive value through the clinical stages of drug development.

Renal proximal tubules are a major target for drug-induced kidney injury (DIKI) that needs evaluation during drug development. Two-dimensional in vitro proximal tubule epithelial cell (PTEC) models are often poor predictors of DIKI, because of the lack of physiological architecture and flow. The team at MIMETAS and Radboud University Medical Centre developed 'NephroScreen' containing of polarized human proximal tubule cells in the OrganoPlate, as a better predictive in vitro system for drug-induced kidney toxicity (DIKI).

In this application note, we explain more about Nephroscreen and elaborate on why it's an ideal model to study the potential toxicity of drugs and other substances involving active uptake via these transporters.


In this App Note, you will learn about:

  • A robust and validated 3D organ-on-a-chip proximal tubule
  • The wide range of compatible readouts, showing identification of nephrotoxicants in line with (pre)clinical compound profiles
  • Why it's an ideal model to study the potential toxicity of drug substances involving active uptake via both organic anion and organic cation transporters

 

Download the app note here

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all